Grace Therapeutics, Inc. Asset Resilience Ratio
Grace Therapeutics, Inc. asset resilience ratio. Grace Therapeutics, Inc. (GRCE) has an Asset Resilience Ratio of 0.02% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GRCE defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Grace Therapeutics, Inc. (2011–2024)
Asset resilience ratio of Grace Therapeutics, Inc. from 2011 to 2024. This chart shows how Grace Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read GRCE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Grace Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GRCE total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.00K | 0.02% |
| Total Liquid Assets | $15.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Grace Therapeutics, Inc. maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grace Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Grace Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Grace Therapeutics, Inc. Asset Resilience Ratio by Year (2011–2024)
Grace Therapeutics, Inc. asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Grace Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 0.00% | $0.00 | $73.30 Million | -- |
| 2023-03-31 | 0.02% | $15.00K | $79.12 Million | -10.34pp |
| 2022-03-31 | 10.36% | $13.32 Million | $128.62 Million | -5.32pp |
| 2021-03-31 | 15.67% | $9.79 Million | $62.46 Million | -8.42pp |
| 2019-03-31 | 24.09% | $8.89 Million | $36.90 Million | -2.01pp |
| 2016-03-31 | 26.10% | $5.49 Million | $21.04 Million | -19.78pp |
| 2015-03-31 | 45.88% | $13.64 Million | $29.74 Million | -4.58pp |
| 2014-03-31 | 50.46% | $20.69 Million | $41.01 Million | +20.98pp |
| 2013-03-31 | 29.48% | $3.50 Million | $11.89 Million | -5.76pp |
| 2012-03-31 | 35.24% | $5.57 Million | $15.82 Million | +12.09pp |
| 2011-03-31 | 23.15% | $2.56 Million | $11.07 Million | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more